Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Better decision making with VIGOR

The VIGOR Unit, a new spin-off of the University of Ghent, will help business leaders and policy makers take effective decisions on the basis of s…


ThromboGenics and VIB found oncology company

Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for…


Trinean wins 25.000 euro for disposables production

Trinean won the “Time for a Boost 2015” competition organized by Test and Measurement Solutions. CEO Kurt Hensen handed a cheque of 25 000 euro to…

POPULAR TAGS

Essenscia/bio.be organizes Dermira and JLABS visits during Bio US!

Written by DS on in the category news with the tags , .


Today, in parallel with the Bio International Convention in San Fransisco, essenscia / bio.be organizes two company visits in California together with Minister of Social Affairs and Public Health, Maggie De Block. On the one hand, they will visit the US-based Dermira in Menlo Park, who has a partnership with the Belgian UCB to develop a cure for psoriasis. On the other hand, they will pay a visit to JLABS in South San Francisco, an innovation centre from Johnson & Johnson that provides laboratory facilities for promising start-ups in biotech on a flexible basis.

Both visits illustrate the strong link between the Belgian and American pharma and biotechnology. More and more Belgian biotech companies join forces with American partners for R&D and venture capital. American companies account for nearly 10,000 jobs in the Belgian life sciences industry.

Via the seminar "Bridging the North American and Belgian excellence in innovative health" at the Bio International Convention, essenscia / bio.be wishes to highlight the innovative strength of the Belgian biopharma and stimulate international collaborations. The testimonies of Paul Stoffels, Johnson & Johnson CEO and Didier Malherbe, General Manager of UCB Belgium, and case presentations from companies such as Amgen and Celyad are scheduled. This seminar, which will also be attended by De Block, was developed in collaboration with essenscia / bio.be, AWEX, FIT, IBE, BioWin, FlandersBio, Lifetech.brussels and Pharma.be.

Read more about: , .

RELATED ARTICLES
Better decision making with VIGOR

The VIGOR Unit, a new spin-off of the University of Ghent, will help business leaders and policy makers take effective decisions on the basis of s…


ThromboGenics and VIB found oncology company

Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for…


Trinean wins 25.000 euro for disposables production

Trinean won the “Time for a Boost 2015” competition organized by Test and Measurement Solutions. CEO Kurt Hensen handed a cheque of 25 000 euro to…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

GSK XpandInnovation Itera Life Science V-Bio Ventures UGent Biowin KU Leuven Janssen Turnstone Flanders.bio

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.